Shares in Teva Pharmaceutical have dipped sharply after reports that the Federal Trade Commission (FTC) has opened an investigation into the company focusing on improperly listed patents in the FDA’s Orange Book.The FTC has been scrutinising the pharma industry to see if drugmakers have used bogus listings to delay the entry of generic competition into the market, and has said it will consider legal action against any companies found to have done so.
